Jump Financial LLC Has $773,000 Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Jump Financial LLC cut its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 79.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,210 shares of the biotechnology company's stock after selling 127,788 shares during the period. Jump Financial LLC's holdings in Exelixis were worth $773,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Fisher Asset Management LLC increased its position in shares of Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 728 shares during the last quarter. Contravisory Investment Management Inc. bought a new position in shares of Exelixis during the 4th quarter valued at approximately $26,000. GAMMA Investing LLC bought a new position in shares of Exelixis during the 4th quarter valued at approximately $27,000. Fifth Third Bancorp increased its position in shares of Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 604 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Exelixis during the 3rd quarter valued at approximately $100,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Price Performance

Exelixis stock traded up $0.15 during midday trading on Monday, reaching $21.06. The company's stock had a trading volume of 1,791,201 shares, compared to its average volume of 2,279,056. The stock's 50-day simple moving average is $22.81 and its 200-day simple moving average is $22.31. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $24.34. The stock has a market capitalization of $6.39 billion, a P/E ratio of 32.91, a PEG ratio of 0.56 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). The business had revenue of $425.23 million during the quarter, compared to analysts' expectations of $461.04 million. Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The company's quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.12 earnings per share. As a group, equities research analysts expect that Exelixis, Inc. will post 1.16 earnings per share for the current fiscal year.

Insider Activity

In other news, Director David Edward Johnson acquired 190,000 shares of the business's stock in a transaction dated Wednesday, February 21st. The shares were acquired at an average cost of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now owns 1,100,730 shares of the company's stock, valued at $22,785,111. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Patrick J. Haley sold 47,020 shares of the firm's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the sale, the executive vice president now directly owns 384,866 shares of the company's stock, valued at $8,255,375.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David Edward Johnson bought 190,000 shares of the company's stock in a transaction that occurred on Wednesday, February 21st. The shares were bought at an average cost of $20.70 per share, for a total transaction of $3,933,000.00. Following the completion of the acquisition, the director now owns 1,100,730 shares of the company's stock, valued at $22,785,111. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 77,148 shares of company stock valued at $1,703,116. Company insiders own 2.85% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. William Blair reissued an "outperform" rating on shares of Exelixis in a research report on Wednesday, May 1st. TD Cowen upped their price objective on Exelixis from $25.00 to $27.00 and gave the company a "buy" rating in a research report on Wednesday, May 1st. Stephens began coverage on Exelixis in a research report on Tuesday, May 14th. They issued an "equal weight" rating and a $23.00 price objective on the stock. TheStreet raised Exelixis from a "c+" rating to a "b-" rating in a research report on Monday, March 18th. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $27.00 price objective on shares of Exelixis in a research report on Wednesday, April 10th. Seven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Exelixis presently has an average rating of "Moderate Buy" and a consensus price target of $26.13.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.